Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials.

Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. Clin Exp Hypertens. 2019 Oct 15;:1-8 Authors: Zhao D, Liu H, Dong P Abstract The antidiabetic effect of liraglutide in patients with type 2 diabetes mellitus has been explored in several trials. We performed this meta-analysis determining the effects of liraglutide on blood pressure in these patients. Three electronic databases (Pubmed, Web of Science, and Cochrane Central) were searched for all published articles evaluating the effects of liraglutide on blood pressure in subjects with type 2 diabetes mellitus. Total 968 patients were included in 10 randomized, double-blind, placebo-controlled trials with a follow-up of 16 ± 9 weeks. Liraglutide 1.8 mg/day reduced systolic blood pressure (weighted mean differences -5.39 (95% confidence interval, -7.26, -3.51) mm Hg, p
Source: Clinical and Experimental Hypertension - Category: Cardiology Authors: Tags: Clin Exp Hypertens Source Type: research

Related Links:

ConclusionsIn Japanese patients with type 2 diabetes mellitus, linagliptin produced sustained reductions in HbA1c and had a safety profile consistent with the established safety profile of linagliptin.Trial RegistrationClinicalTrials.gov (NCT01650259).
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
This study was designed to evaluate the influences of long-term metformin prescription in these patients.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
A 59-year-old man with type 2 diabetes mellitus and hypertension presented to the emergency department with a 4-day history of coughing and an intermittent fever. He had received ultrasonography-guided percutaneous puncture via left flank with ethanol injection for renal cyst sclerosing therapy approximately 2  weeks earlier. On physical examination, he was well oriented and febrile (39.8°C) with high blood pressure (194/88 mm Hg) and tachycardia (heart rate 131 beats/min). His abdomen and back were soft without tenderness or erythematous change.
Source: The Journal of Emergency Medicine - Category: Emergency Medicine Authors: Tags: Visual Diagnosis in Emergency Medicine Source Type: research
AbstractBackgroundDipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose co-transporter 2 (SGLT2) inhibitors are widely used antidiabetic drugs. However, to date, no studies have directly compared the effects of these two drugs on the components of the metabolic syndrome in patients with type 2 diabetes mellitus (T2DM).ObjectivesThe Comparison of Canagliflozin vs. Teneligliptin against Basic Metabolic Risks in Patients with T2DM (CANTABILE) study aims to examine whether the DPP-4 inhibitor (teneligliptin) or the SGLT2 inhibitor (canagliflozin) is the more effective drug for reducing metabolic risk factors as a compos...
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
ConclusionDiabetes prevalence was 6.9% and was higher in older people, people with hypertension, alcohol consumers and abdominally obese men.
Source: Journal of Public Health - Category: Health Management Source Type: research
Publication date: Available online 23 October 2019Source: The Journal of Steroid Biochemistry and Molecular BiologyAuthor(s): Margarida Lorigo, Melissa Mariana, Manuel C. Lemos, Elisa CairraoAbstractTestosterone (T) is the predominant endogenous androgen in the bloodstream. At the vascular level, T presents genomic and non-genomic effects, and both effects may overlap. The genomic actions assume that androgens can freely cross the plasma membrane of target cells and bind to nuclear androgen receptors, inducing gene transcription and protein synthesis. The non-genomic effects have a more rapid onset and may be related to th...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
Type 2 diabetes mellitus (T2DM) is a chronic, metabolic disease, which is increasing dramatically worldwide [1,2]. For T2DM patients with hypertension, lipid levels and blood pressure control is important to prevent cardiovascular disease complications [3,4]. Poorly controlled blood glucose can cause both macrovascular and microvascular complications [5]. Glycated hemoglobin (HbA1c) has been proven as a more comprehensive measure of total glycemic control than fasting plasma glucose, and it is highly associated with the presence of diabetic micro-vascular complications in prospective studies [6].
Source: Primary Care Diabetes - Category: Primary Care Authors: Tags: Original research Source Type: research
A 65-year-old man was admitted with slurred speech of acute onset. He had a past medical history of type 2 diabetes mellitus, hypertension and bipolar disorder on metformin, amlodipine and lithium. He had difficulty pronouncing simple words and was speaking incoherently. He seemed confused and had difficulty walking. There had been no recent falls, head trauma or alcohol ingestion.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Clinical Communications to the Editor Source Type: research
Authors: D'Anna R, Santamaria A, Alibrandi A, Corrado F, DI Benedetto A, Facchinetti F Abstract Gestational Diabetes Mellitus (GDM) is one of the most frequent complications of pregnancy and is characterized by a carbohydrate intolerance which is diagnosed with the oral glucose tolerance test. The prevalence of GDM in our population is about 12%, but risk factors like a previous GDM, ethnicity, a parent with diabetes mellitus type 2 and maternal overweight may increase its occurrence. Complications of GDM are a pre-term birth (before 37 wk gestation), macrosomia (birth weight ≥4 kg) and gestational hypertension....
Source: Journal of Nutritional Science and Vitaminology - Category: Nutrition Tags: J Nutr Sci Vitaminol (Tokyo) Source Type: research
Authors: Andreeva-Gateva PA, Mihaleva ID, Dimova II Abstract Diabetes mellitus and cardiovascular diseases are part of the metabolic syndrome and share similar risk factors, including obesity, arterial hypertension, and dyslipidemia. Atherosclerosis and insulin resistance contribute to the development of the diseases, and subclinical inflammation is observed in both conditions. There are many proofs about the connection between epigenetic factors and different diseases, including diabetes and cardiovascular diseases. Interestingly, recent studies show that at least some anti-diabetic drugs, as well as blockers of t...
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
More News: Cardiology | Cardiovascular | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Hypertension | Science | Victoza | Weight Loss